Navigation Links
DATATRAK International Reports First Quarter Results for 2008
Date:5/8/2008

ding sales momentum as we entered this year and felt we were moving in such a direction that we believed 2008 would place us back on a positive sales growth trend," stated Dr. Jeffery A. Green, President and CEO of DATATRAK International, Inc. "This optimism was supported by a near record volume of approximately $4.1 million of new business during the fourth quarter of 2007, a reflection of positive results from our reorganized marketing and sales efforts. We were careful to frame our anticipated return to growth as a gradual, but positive trend, stating it was certainly possible that as we progressed through the remainder of 2008 and beyond, a particular quarter's sales may not necessarily be greater than the prior, however, looking out, the trend should be progressively upward."

Green Continued, "Based partially on our first quarter 2008 revenues, which represented our first sequential quarterly revenue increase in quite some time (going from $1.8 million in the fourth quarter of 2007 to $2.1 million during the first quarter of this year) and new backlog additions totaling approximately $3 million, I am pleased to report to you today that during this first quarter we continued to make progress towards achieving our recovery goals for 2008."

"Our relationship with NTT DATA continues to advance. During this quarter our respective teams have been working closely on continued training on our eClinical platform and we are working hand-in-hand with NTT DATA's marketing and sales team in Japan. NTT DATA will be present in our booth at the upcoming Annual DIA trade show in Boston in June."

"While challenges and uncertainties still confront us, we are encouraged with our progress during the most recent quarter and remain positive about our future potential. We are focused on, and working to return the Company to a positive cash flow environment as quickly as possible. I encourage you to join our conference call later today where these and other topics
'/>"/>

SOURCE DATATRAK International, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. DATATRAK and COResearch to Collaborate on Six Cardiac Safety Projects
2. DATATRAK(TM) Takes Clinical Trial Solutions to the Next Level With the Release of 5.0
3. Patients Treated with Risperidone Long-Acting Injection had a Significantly Longer Time to Relapse Compared to Quetiapine in International Clinical Study
4. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
5. New Research for Mechanical Support Devices in Pediatrics to Be Released at International Heart and Lung Transplant Meeting
6. International ACTEMRA Rheumatoid Arthritis Study Highlighted in The Lancet
7. UMDNJ-University Hospital in Newark to Tailor Diabetes Interventions for Low-Income and Minority Groups With Grant From the International Diabetes Federation
8. Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment
9. Molecular Biometrics Hires Denny Sakkas, PhD Renowned Yale Embryologist and International Thought-Leader, as Chief Scientific Officer; Opening U.S. Research Facility
10. Steps Toward Stopping Autoimmune Disease: International Consortium Identifies Genes Linked to Lupus
11. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today ... patients in its ongoing Phase 2 trial (Study 202) ... revised clinical protocol agreed to with the FDA in ... proprietary recombinant human hyaluronidase under development for the systemic ... "Our diligent effort to rapidly re-initiate patient enrollment and ...
(Date:7/22/2014)... ,  July 22, 2014 The ... Thomson Reuters , the world,s leading provider ... today announced Cortellis Clinical Trials Intelligence ... an industry-first milestone with the documentation of ... pharmaceutical professionals with greater and quicker access ...
(Date:7/22/2014)...  Neurotrope Bioscience, Inc., a subsidiary of Neurotrope, Inc. ... with the Icahn School of Medicine at ... ) to utilize its proprietary information and data package ... Niemann-Pick Type C Disease (NPC), a rare disease, mostly ... license also covers other diseases and disorders relying on ...
Breaking Medicine Technology:Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 2Thomson Reuters Cortellis Clinical Trials Intelligence Reaches Industry Milestone with 180,000 Clinical Trials 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 2Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 3Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 4Neurotrope Enters Collaborative Agreement with Icahn School of Medicine at Mount Sinai for use of Bryostatin-1 in the Treatment of Niemann-Pick Disease Type C 5
(Date:7/22/2014)... CA (PRWEB) July 22, 2014 As reported ... to a caller request to name her favorite beauty products, ... went on to say that “ Botox has changed ... in the makeup chair preparing for her various, daily appearances. ... eyelashes,” explained Ms. Ripa (see: goo.gl/shmTQM). , “I think that ...
(Date:7/22/2014)... Latin American Conference on Lung Cancer (LALCA 2014) will ... Peru. , Lung Cancer is still the leading cause ... Building on the success of the previous conferences in ... will discuss the science and advances in the treatment ... and Latin America in particular. , With tobacco being ...
(Date:7/22/2014)... 2014 The Entertainment Industries Council, Inc. ... educational tools and recognition activities for thousands of entertainment ... treatment and recovery. On July 24, 2014, at 8pm, ... of these resources with a special mention of the ... treatment website at the end of the show. ...
(Date:7/22/2014)... HealthDay Reporter TUESDAY, July ... minimally invasive procedure known as morcellation carries a risk of ... likelihood more clearly. Twenty-seven of every 10,000 women who ... of the procedure, researchers found, with the odds being highest ... a hysterectomy with morcellation use a power cutter to slice ...
(Date:7/22/2014)... 22, 2014 5i Sciences, a medical ... appointment of Molly Coye, M.D., M.P.H. to a role ... renowned authority on the market introduction of innovative technologies ... she will advise on strategies for building a successful ... technology. Dr. Coye is currently the Chief Innovation ...
Breaking Medicine News(10 mins):Health News:Celebrity Botox: Kelly Ripa Confesses to Getting Botox Injections 2Health News:ABC’s BLACK BOX Spotlights Mental Health and Available Resources in Upcoming Episode 2Health News:Technique Used in Some Hysterectomies May Help Spread Cancer: Study 2Health News:Technique Used in Some Hysterectomies May Help Spread Cancer: Study 3Health News:5i Sciences Announces Appointment of a Senior Healthcare Consultant and Successful Financing 2
... multispecialty medical group in Southern California, announced the opening of its ... Monrovia. , ... Torrance, CA (PRWEB) December 16, 2008 ... Southern California, announced the opening of its newest medical office ...
... portal that features the latest news, facts and nutritional updates about ... acai plant and the acai berry fruit to help the general ... ... Dallas, TX (PRWEB) December 16, 2008 -- The announcement ...
... Inc.(CTI),(Nasdaq and MTA: CTIC) announced today they have ... a 50/50 owned joint venture, RIT,Oncology LLC (LLC), ... United States. In connection with the closing, ... and will receive an,additional $7.5 million in early ...
... Dec. 15 Today, the U.S. Food,and Drug Administration ... along with diet to help lower triglycerides,and LDL cholesterol, ... TRILIPIX is the first and only fibrate to ... In certain patients, treatment guidelines,recommend the combination of a ...
... Calif.) -- A secondary analysis of a large, multicenter ... fruits, vegetables and fiber and somewhat lower in fat ... of recurrence in a subgroup of early-stage breast cancer ... by approximately 31 percent. These patients typically have higher ...
... say , , MONDAY, Dec. 15 (HealthDay News) -- Men ... spread beyond the wall of the prostate gland -- ... risk of dying in half, a new study has ... much longer, the Swedish research team concluded. In fact, ...
Cached Medicine News:Health News:HealthCare Partners Opens a New Medical Office in Monrovia, CA 2Health News:AcaiBerryMD.com Explains the Real Facts About the Acai Berry Fruit 2Health News:AcaiBerryMD.com Explains the Real Facts About the Acai Berry Fruit 3Health News:Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US 2Health News:Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US 3Health News:Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US 4Health News:Cell Therapeutics and Spectrum Pharmaceuticals Close Transaction Forming Joint Venture to Market Zevalin in the US 5Health News:(Multimedia Version): Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 2Health News:(Multimedia Version): Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 3Health News:(Multimedia Version): Abbott Receives FDA Approval for TRILIPIX(TM) (fenofibric acid), First and Only Fibrate Indicated for Use in Combination With a Statin for Cholesterol Management 4Health News:Diet may cut risk of breast cancer recurrence in women without hot flashes 2Health News:Diet may cut risk of breast cancer recurrence in women without hot flashes 3Health News:Radiation Plus Hormone Therapy Cuts Prostate Cancer Deaths 2Health News:Radiation Plus Hormone Therapy Cuts Prostate Cancer Deaths 3
... The AlphaPette Pipettor is the #1 ... Offers accuracy, comfort, and reliability. Continuously ... volume readout sub-micrometer. Easy interchangeable ejector ... tiny hands. Adjustable rapid pipet tip ...
... The Finnpipette Digital offers improved ergonomics ... rounded handle, modified grippy finger rest ... operator comfort and efficiency. Finnpipette Digitals ... power-boosted gearing mechanism (pat. pend.) and ...
... is the #1 Pipettor for sub-microliter ... and reliability. Continuously adjustable. Features lPLUS, ... Easy interchangeable ejector buttons to fit ... rapid pipet tip ejector with three ...
... Recommended for aqueous samples of moderate viscosity and density. Proven ergonomic design ... Volume Range(ul) ... 0.8~1.5 Imprecision(%) ... (ul) ...
Medicine Products: